Maristela Corrêa de Lima, Célia Marisa Rizzatti Barbosa, Maria Beatriz Duarte Gavião, Paulo Henrique Ferreira Caria
{"title":"低剂量肉毒杆菌毒素是否能有效控制睡眠磨牙症、清醒磨牙症和颞下颌关节紊乱症的慢性疼痛?","authors":"Maristela Corrêa de Lima, Célia Marisa Rizzatti Barbosa, Maria Beatriz Duarte Gavião, Paulo Henrique Ferreira Caria","doi":"10.1080/08869634.2021.1973215","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the effects of low doses of botulinum toxin type A (BoNT-A) to control pain in patients with sleep bruxism (SB), awake bruxism (AB), and temporomandibular disorder (TMD) during 180 days.</p><p><strong>Methods: </strong>Overall sample of thirty-five patients with chronic pain related to TMD, SB, and AB received a single dose of 20 U of BoNT-A in masseter and temporalis muscles. The pain was assessed with a visual analog scale (VAS) before and after 15, 30, 60, 90, and 180 days of the application.</p><p><strong>Results: </strong>The three clinical conditions experienced decrease in pain after 15 days of treatment (<i>p</i> < 0.0001); the maximum pain relief persisted for up to 90 days after BoNT-A application in patients with SB and AB and 15 days for patients with TMD.</p><p><strong>Conclusion: </strong>A low dose of BoNT-A may be effective for controlling chronic pain related to SB and AB, but TMD pain reduction was short-lived.</p>","PeriodicalId":56318,"journal":{"name":"Cranio-The Journal of Craniomandibular & Sleep Practice","volume":" ","pages":"421-428"},"PeriodicalIF":2.0000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Is low dose of botulinum toxin effective in controlling chronic pain in sleep bruxism, awake bruxism, and temporomandibular disorder?\",\"authors\":\"Maristela Corrêa de Lima, Célia Marisa Rizzatti Barbosa, Maria Beatriz Duarte Gavião, Paulo Henrique Ferreira Caria\",\"doi\":\"10.1080/08869634.2021.1973215\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>To evaluate the effects of low doses of botulinum toxin type A (BoNT-A) to control pain in patients with sleep bruxism (SB), awake bruxism (AB), and temporomandibular disorder (TMD) during 180 days.</p><p><strong>Methods: </strong>Overall sample of thirty-five patients with chronic pain related to TMD, SB, and AB received a single dose of 20 U of BoNT-A in masseter and temporalis muscles. The pain was assessed with a visual analog scale (VAS) before and after 15, 30, 60, 90, and 180 days of the application.</p><p><strong>Results: </strong>The three clinical conditions experienced decrease in pain after 15 days of treatment (<i>p</i> < 0.0001); the maximum pain relief persisted for up to 90 days after BoNT-A application in patients with SB and AB and 15 days for patients with TMD.</p><p><strong>Conclusion: </strong>A low dose of BoNT-A may be effective for controlling chronic pain related to SB and AB, but TMD pain reduction was short-lived.</p>\",\"PeriodicalId\":56318,\"journal\":{\"name\":\"Cranio-The Journal of Craniomandibular & Sleep Practice\",\"volume\":\" \",\"pages\":\"421-428\"},\"PeriodicalIF\":2.0000,\"publicationDate\":\"2024-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cranio-The Journal of Craniomandibular & Sleep Practice\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/08869634.2021.1973215\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2021/9/6 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"DENTISTRY, ORAL SURGERY & MEDICINE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cranio-The Journal of Craniomandibular & Sleep Practice","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/08869634.2021.1973215","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/9/6 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"DENTISTRY, ORAL SURGERY & MEDICINE","Score":null,"Total":0}
引用次数: 0
摘要
目的评估低剂量 A 型肉毒毒素(BoNT-A)在 180 天内控制睡眠磨牙症(SB)、清醒磨牙症(AB)和颞下颌关节紊乱症(TMD)患者疼痛的效果:方法:对 35 名患有 TMD、SB 和 AB 相关慢性疼痛的患者进行抽样调查,这些患者的咀嚼肌和颞肌接受了单剂量 20 U BoNT-A。在使用前和使用 15、30、60、90 和 180 天后,用视觉模拟量表(VAS)对疼痛进行评估:结果:三种临床症状在治疗 15 天后疼痛均有所减轻(P < 0.0001);SB 和 AB 患者在使用 BoNT-A 后的最大疼痛缓解持续了 90 天,TMD 患者在使用 BoNT-A 后的最大疼痛缓解持续了 15 天:结论:小剂量 BoNT-A 可有效控制与 SB 和 AB 相关的慢性疼痛,但 TMD 疼痛的缓解持续时间较短。
Is low dose of botulinum toxin effective in controlling chronic pain in sleep bruxism, awake bruxism, and temporomandibular disorder?
Objective: To evaluate the effects of low doses of botulinum toxin type A (BoNT-A) to control pain in patients with sleep bruxism (SB), awake bruxism (AB), and temporomandibular disorder (TMD) during 180 days.
Methods: Overall sample of thirty-five patients with chronic pain related to TMD, SB, and AB received a single dose of 20 U of BoNT-A in masseter and temporalis muscles. The pain was assessed with a visual analog scale (VAS) before and after 15, 30, 60, 90, and 180 days of the application.
Results: The three clinical conditions experienced decrease in pain after 15 days of treatment (p < 0.0001); the maximum pain relief persisted for up to 90 days after BoNT-A application in patients with SB and AB and 15 days for patients with TMD.
Conclusion: A low dose of BoNT-A may be effective for controlling chronic pain related to SB and AB, but TMD pain reduction was short-lived.
期刊介绍:
CRANIO: The Journal of Craniomandibular & Sleep Practice is the oldest and largest journal in the world devoted to temporomandibular disorders, and now also includes articles on all aspects of sleep medicine. The Journal is multidisciplinary in its scope, with editorial board members from all areas of medicine and dentistry, including general dentists, oral surgeons, orthopaedists, radiologists, chiropractors, professors and behavioural scientists, physical therapists, acupuncturists, osteopathic and ear, nose and throat physicians.
CRANIO publishes commendable works from outstanding researchers and clinicians in their respective fields. The multidisciplinary format allows individuals practicing with a TMD emphasis to stay abreast of related disciplines, as each issue presents multiple topics from overlapping areas of interest.
CRANIO''s current readership (thousands) is comprised primarily of dentists; however, many physicians, physical therapists, chiropractors, osteopathic physicians and other related specialists subscribe and contribute to the Journal.